- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05635071
Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1)Clinical diagnosis of uterine adhesions; 2)Body mass index between 18-27 kg/m2; 3)Have a regular menstrual cycle of 27-35 days for at least six months; 4)Hysteroscopic diagnosis of moderate to severe uterine adhesions (AFS score >5), treated with electrodesiccation; 5)No contraindications to oral estrogen and progestin such as a history of thrombosis/breast tumor/history of abnormal liver function/migraine; 6)≥ 2 oocytes or blastocysts have been frozen.
Exclusion Criteria:
1)Patients with combined ovarian cysts ≥ 20 mm in diameter, submucosal uterine fibroids or intermuscular fibroids > 30 mm in diameter, pituitary tumors, and malignant tumors of various tissues and organs; 2)Patients with clinically significant abnormalities of the uterus (endometrial polyps, uterine malformations, endometriosis) and adnexa (hydrosalpinx); 3)Repeated implantation failures, such as three consecutive transfers with ≥6 failed high-quality embryos; 4)Known malformations of the reproductive organs that are unsuitable for pregnancy; 5)Abnormal cervical cytology (TCT) findings within 1 year before the screening; 6)Severe liver or kidney impairment, heart disease, or hypertension; 7)Known previous or current history of thrombophlebitis or thromboembolic disease; 8)Any known clinically significant systemic disease (e.g., diabetes mellitus, tuberculosis, etc; 9)Known history of recurrent miscarriage; 10)Chromosomal karyotype abnormalities in either spouse; 11)Genetic disorders that make either spouse unsuitable for childbirth as specified in the Maternal and Child Health Law;12)exposure of either spouse to teratogenic amounts of radiation, toxins, and drugs; 13)Participation in another drug or medical device clinical trial within 3 months before enrollment;14)Any medical condition/combined surgery/ medication/other clinically significant abnormal laboratory tests that, in the judgment of the investigator, may affect the outcome of the trial; 15)Known refusal or inability to comply with protocol requirements for any reason (including planned clinical visits and examinations).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nintedanib 100mg
Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 100mg bid *15 days orally.
|
Nintedanib 100mg bid *15 days orally after hysteroscopic surgery
Other Names:
|
Experimental: Nintedanib 150mg
Traditional hormone replacement (HRT) cycle medication (Tegretol 2mg bid for 20 days, followed by Darvon 10mg bid for the last 10 days) + Nintedanib 150mg bid *15 days orally.
|
Nintedanib 150mg bid *15 days orally after hysteroscopic surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American Fertility Association(AFS) score (mild:1-4,moderate:5-8,severe:9-12)
Time Frame: 3 months
|
American Fertility Association(AFS) scoring performed hysteroscopically
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endometrial thickness
Time Frame: 3 months
|
Endometrial thickness measured by ultrasonography
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022ZSLYEC-492
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Adhesions
-
Ain Shams UniversityCompleted
-
Fu Xing Hospital, Capital Medical UniversityUnknown
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Endometritis | Intrauterine Adhesions
-
Karnataka Institute of Medical SciencesCompletedTissue Adhesions | Nasal Synechiae | Adhesions of Nasal Cavity | Nasal AdhesionsIndia
-
University of SurreyEthicon Endo-SurgeryCompleted
-
University Hospital TuebingenCompleted
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownChronic Pain | Adhesions Abdominal | Surgery Induced Tissue Adhesions | Adhesions PelvicNetherlands
-
The University of Hong KongRecruitingSurgical AdhesionsHong Kong
-
Baxter Healthcare CorporationCompletedIntraperitoneal AdhesionsDenmark, Poland, Sweden
Clinical Trials on Nintedanib 100 MG [Ofev]
-
Boehringer IngelheimCompleted
-
Holdsworth House Medical PracticeBoehringer IngelheimRecruitingSilicosis | Pneumoconiosis Coal | AsbestosisAustralia
-
Assistance Publique - Hôpitaux de ParisBoehringer IngelheimRecruitingSARS-Cov-2 Induced Pulmonary FibrosisFrance
-
Boehringer IngelheimCompletedHealthyUnited Kingdom
-
Boehringer IngelheimActive, not recruitingLung Diseases, InterstitialUnited States, Spain, United Kingdom, Canada, Finland, Norway, Italy, Argentina, Belgium, Brazil, Czechia, France, Greece, Mexico, Poland, Germany, Portugal
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
McGill University Health Centre/Research Institute...RecruitingInterstitial Lung Disease | Myopathy, InflammatoryCanada
-
Hal ChapmanMassachusetts General Hospital; University of Michigan; University of Washington and other collaboratorsRecruitingIdiopathic Pulmonary FibrosisUnited States
-
Boehringer IngelheimNo longer available
-
Boehringer IngelheimCompletedIdiopathic Pulmonary FibrosisKorea, Republic of